Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma

Figure 7

Efficacy prediction of chemotherapy drugs. (a) IC₅₀ of 12 chemotherapy agents in different risk groups. (b) Comparison of the risk score between response and nonresponse subgroups in TACE cohort (GSE104580) (c) The proportion of chemotherapy response (response and nonresponse) in TACE cohort. (d) ROC analysis of the risk score on the response rate in TACE cohort. (e) Comparison of the risk score between response and nonresponse subgroups in the sorafenib cohort (GSE109211). (f) The proportion of chemotherapy response (response and nonresponse) in the sorafenib cohort. (g) ROC analysis of the risk score on the response rate in the sorafenib cohort.

(a)

(b)

(c)

(d)

(e)

(f)

(g)